<DOC>
	<DOCNO>NCT01946620</DOCNO>
	<brief_summary>Efficacy Fluticasone/Formoterol COPD Treatment . The Effect study .</brief_summary>
	<brief_title>A Study Show That Flutiform Well Tolerated Effective Treatment COPD</brief_title>
	<detailed_description>This study multi-centre , randomise , double-blind , active-controlled , parallel-group study , male female subject assign 1 3 treatment group base 1:1:1 ratio . Following 2 week run-in phase subject receive treatment 1 year ( 52 week ) follow final follow 2 week last visit , time subject require attend 10 clinic visit final follow complete telephone . Throughout study subject assess mixture symptom base measurement well lung function test monitor progress study .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Inclusion : 1 . Male Female subject age ≥ 40 year screen visit : 1 . Female subject child bear potential ( less 1 year postmenopausal ) must negative urine pregnancy test prior first dose study medication , nonlactating , willing use adequate highly effective method birth control throughout study sterilisation , implant , injectables , combine oral contraceptive , intrauterine device , sexual abstinence vasectomise partner . 2 . Male subject partner child bear potential must willing use adequate highly effective method birth control throughout study 2 . Smoking history ≥10 pack per year . 3 . Diagnosis COPD 4 . History ≥ moderate severe COPD exacerbation previous year . 5 . Willing able replace current COPD therapy study medication . 6 . Able demonstrate correct use pMDI without spacer . 7 . Willing able attend study visit complete study assessment . 8 . Able provide sign informed consent . Exclusion : 1 . Ongoing moderate severe exacerbation COPD ( see section 10 ) 2 . Current diagnosis asthma 3 . Documented evidence α1antitrypsin deficiency underlie cause COPD 4 . Other active respiratory disease active tuberculosis , lung cancer , bronchiectasis , sarcoidosis , lung fibrosis , pulmonary hypertension , interstitial lung disease , cystic fibrosis , bronchiolitis obliterans 5 . Previous lung resection 6 . Use longterm oxygen therapy ( LTOT ) least 12 hour daily mechanical ventilation 7 . Chest Xray CT scan reveals evidence clinically significant abnormality reflective active disease believe due COPD 8 . Evidence uncontrolled cardiovascular disease 9 . Evidence clinically significant renal , hepatic , gastrointestinal , psychiatric disease 10 . Current malignancy previous history cancer remission &lt; 5 year ( basal cell squamous cell carcinoma skin resect exclude ) 11 . Clinically significant sleep apnoea require use continuous positive airway pressure ( CPAP ) device noninvasive positive pressure ventilation ( NIPPV ) device 12 . Participation acute phase pulmonary rehabilitation programme within 4 week prior screen study 13 . Known suspected history drug alcohol abuse last 2 year 14 . Requiring treatment prohibit concomitant medication 15 . Known suspected hypersensitivity contraindication study drug excipients 16 . Received investigational drug within 30 day screen visit ( 12 week oral injectable steroid ) .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>Exacerbations</keyword>
	<keyword>FEV1 ≤ 50 %</keyword>
</DOC>